三特异性抗体在肿瘤免疫治疗中的研究进展
Research progress of trispecific antibodies in tumor immunotherapy
许林 1宁文静 1刘雪 1罗文新1
作者信息
- 1. 厦门大学公共卫生学院,国家传染病诊断试剂与疫苗工程技术研究中心,厦门 361102
- 折叠
摘要
三特异性抗体(trispecific antibodies,TsAbs)是一种可以同时靶向肿瘤细胞或免疫效应细胞三种不同抗原结合位点的创新疗法.与单克隆抗体和双特异性抗体相比,三特异性抗体可增加结合特异性,降低脱靶毒性,在肿瘤免疫治疗领域具有广阔的应用前景.本文主要介绍了三特异性抗体的发展进程、主要构建形式及其作用机制,总结了不同靶点组合的代表性药物的最新研究进展,并讨论了其存在的挑战和未来发展方向,旨在为三特异性抗体药物的发展提供新思路.
Abstract
Trispecific antibodies(TsAbs)are innovative therapies that target three different antigen-binding sites on tumor cells or immune effector cells simultaneously.Compared with monoclonal antibodies and bispecific antibodies,TsAbs can increase binding specificity and reduce off-target toxicity,offering broad application prospects in the field of tumor immunotherapy.In this paper,we introduce the development process,main construction forms,and mechanism of action of TsAbs.Furthermore,we summarize the latest research progress on representative drugs with different target combinations.Finally,we discuss the challenges and future development directions of TsAbs,aiming to provide new ideas for the development of trispecific antibody drugs.
关键词
三特异性抗体/肿瘤免疫疗法/CD3/T细胞接合器/免疫检查点Key words
trispecific antibodies/cancer immunotherapy/CD3/T cell engager/immune checkpoints引用本文复制引用
基金项目
国家自然科学基金(32070940)
博士后创新人才支持计划(BX20220189)
出版年
2024
NETL
NSTL
万方数据